Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom’s Macroglobulinemia

Inclusion Criteria:

18 years of age or older
Patients must have received prior therapies for their WM and have relapsed or refractory WM requiring therapy. Any number of prior therapies is acceptable. Patients must not have been refractory to rituximab. The last rituximab must be at least 3 months prior to the start of treatment. Prior treatment with bortezomib and/or everolimus is permitted.
Measurable monoclonal IgM protein in the serum OR measurable quantitative immunoglobulin M (serum IgM).
Lymphoplasmacytic cells in the bone marrow during any previous bone marrow biopsy.
CD20 positive disease based on any previous bone marrow immuno-histochemistry or flow cytometric analysis performed prior to enrollment.
ECOG Performance Status 0, 1 or 2
Laboratory values as outlined in the protocol
Capable of swallowing intact study medication tablets
Life expectancy of 12 weeks or greater

Exclusion Criteria:

Uncontrolled infection
Other active malignancies
Cytotoxic chemotherapy 3 weeks or less, or biologic or targeted novel therapy 2 weeks or less, or corticosteroids 2 weeks or less, or radiation therapy 2 weeks or less, or any ancillary treatment considered investigation 2 weeks or less, prior to registration. Patients may be receiving chronic corticosteroids if they are being given for disorders other than WM.
Pregnant women, nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception throughout the trial and for 8 weeks after the last dose of study treatment.
Known to be HIV positive, or Hepatitis B positive. If the status of HIV is not known and patients are not at risk, then patients will not be specifically tested for HIV. Patients will be tested for Hepatitis B at time of screening. If patients are not considered high risk and have been vaccinated at an earlier date, results of the test are not required at the time of registration. For patients that are high risk, results must be obtained prior to registration.
Patient has Grade 2 or higher peripheral neuropathy within 14 days of enrollment
Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection fo basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
Severely impaired lung function
Uncontrolled diabetes
Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Impairment of gastrointestinal function or gastrointestinal disease
Patients with active, bleeding diathesis
Myocardial infarction within 6 months prior to enrollment or had NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
Hypersensitivity to everolimus or other rapamycins or to is excipients
Patients who may need or are receiving live vaccines for immunization
Serious medical or psychiatric illness likely to interfere with participation in this clinical study